Brain-Derived Neurotrophic Factor Levels in Cannabis Use Disorders - A Systematic Review and Meta-Analysis

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2023 Oct 30

PMID 37900486

Authors

Palani S Mohanraj

Arani Das

Aniruddha Sen

Manoj Prithviraj

Affiliations

Soon will be listed here.

Abstract

The prevalence of cannabis use disorders has become a noteworthy global public health issue. Understanding the neurobiological factors associated with cannabis use disorder (CUD) is crucial for creating effective interventions. One such factor, the brain-derived neurotrophic factor (BDNF), has been linked to the onset and persistence of addictive behaviors. This systematic review aims to summarize the existing literature on BDNF levels in individuals with CUD to provide a comprehensive overview of the current evidence. A systematic search was conducted using electronic databases (PubMed, Scopus) for relevant studies. The search approach yielded a total of 785 articles, with 559 located in the PubMed database and 226 in Scopus. Studies reporting BDNF levels in individuals with CUD compared to healthy controls were included in this study. Ultimately, eight articles were included in this systematic review. The primary emphasis of these studies was on individuals who were cannabis users or had a dependency on cannabis. There is considerable variation in the estimated effect size among included studies due to heterogeneity; hence, a random effect model was used for meta-analysis. The findings of our study suggest that the effect size of BDNF levels was 0.25 with 95% CI (-0.55; 1.05) in cannabis users, which was not statistically significant (p-value=0.54). Therefore, it is important to interpret the results with caution, and additional research is warranted to investigate the potential factors contributing to this heterogeneity.

Citing Articles

Effect of cannabis use on blood levels of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF): A systematic review and meta-analysis.

Shafiee A, Rafiei M, Jafarabady K, Eskandari A, Abhari F, Sattari M Brain Behav. 2024; 14(1):e3340.

PMID: 38376038 PMC: 10757895. DOI: 10.1002/brb3.3340.

References

Angelucci F, Gruber S, El Khoury A, Tonali P, Mathe A . Chronic amphetamine treatment reduces NGF and BDNF in the rat brain. Eur Neuropsychopharmacol. 2007; 17(12):756-62. DOI: 10.1016/j.euroneuro.2007.03.002. View

Hyman C, Hofer M, Barde Y, Juhasz M, Yancopoulos G, Squinto S . BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature. 1991; 350(6315):230-2. DOI: 10.1038/350230a0. View

Sundram S . Cannabis and neurodevelopment: implications for psychiatric disorders. Hum Psychopharmacol. 2006; 21(4):245-54. DOI: 10.1002/hup.762. View

Toll A, Berge D, Burling K, Scoriels L, Treen D, Monserrat C . Cannabis use influence on peripheral brain-derived neurotrophic factor levels in antipsychotic-naïve first-episode psychosis. Eur Arch Psychiatry Clin Neurosci. 2020; 270(7):851-858. DOI: 10.1007/s00406-020-01117-y. View

Devane W, Dysarz 3rd F, Johnson M, Melvin L, Howlett A . Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol. 1988; 34(5):605-13. View

Miranda M, Morici J, Zanoni M, Bekinschtein P . Brain-Derived Neurotrophic Factor: A Key Molecule for Memory in the Healthy and the Pathological Brain. Front Cell Neurosci. 2019; 13:363. PMC: 6692714. DOI: 10.3389/fncel.2019.00363. View

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021; 10(1):89. PMC: 8008539. DOI: 10.1186/s13643-021-01626-4. View

Bolla K, Brown K, Eldreth D, Tate K, Cadet J . Dose-related neurocognitive effects of marijuana use. Neurology. 2002; 59(9):1337-43. DOI: 10.1212/01.wnl.0000031422.66442.49. View

Tadijan A, Vlasic I, Vlainic J, dikic D, Orsolic N, Jazvinscak Jembrek M . Intracellular Molecular Targets and Signaling Pathways Involved in Antioxidative and Neuroprotective Effects of Cannabinoids in Neurodegenerative Conditions. Antioxidants (Basel). 2022; 11(10). PMC: 9598923. DOI: 10.3390/antiox11102049. View

10.

Solowij N, Stephens R, Roffman R, Babor T, Kadden R, Miller M . Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA. 2002; 287(9):1123-31. DOI: 10.1001/jama.287.9.1123. View

11.

Miguez M, Chan W, Espinoza L, Tarter R, Perez C . Marijuana use among adolescents is associated with deleterious alterations in mature BDNF. AIMS Public Health. 2019; 6(1):4-14. PMC: 6433615. DOI: 10.3934/publichealth.2019.1.4. View

12.

Korte M, Carroll P, Wolf E, Brem G, Thoenen H, Bonhoeffer T . Hippocampal long-term potentiation is impaired in mice lacking brain-derived neurotrophic factor. Proc Natl Acad Sci U S A. 1995; 92(19):8856-60. PMC: 41066. DOI: 10.1073/pnas.92.19.8856. View

13.

Archie S, Cucullo L . Harmful Effects of Smoking Cannabis: A Cerebrovascular and Neurological Perspective. Front Pharmacol. 2020; 10:1481. PMC: 6915047. DOI: 10.3389/fphar.2019.01481. View

14.

Lu L, Grimm J, Shaham Y, Hope B . Molecular neuroadaptations in the accumbens and ventral tegmental area during the first 90 days of forced abstinence from cocaine self-administration in rats. J Neurochem. 2003; 85(6):1604-13. DOI: 10.1046/j.1471-4159.2003.01824.x. View

15.

DSouza D, Pittman B, Perry E, Simen A . Preliminary evidence of cannabinoid effects on brain-derived neurotrophic factor (BDNF) levels in humans. Psychopharmacology (Berl). 2008; 202(4):569-78. PMC: 2791800. DOI: 10.1007/s00213-008-1333-2. View

16.

Angelucci F, Ricci V, Spalletta G, Pomponi M, Tonioni F, Caltagirone C . Reduced serum concentrations of nerve growth factor, but not brain-derived neurotrophic factor, in chronic cannabis abusers. Eur Neuropsychopharmacol. 2008; 18(12):882-7. DOI: 10.1016/j.euroneuro.2008.07.008. View

17.

Bayazit H, Dulgeroglu D, Selek S . Brain-Derived Neurotrophic Factor and Oxidative Stress in Cannabis Dependence. Neuropsychobiology. 2019; 79(3):186-190. DOI: 10.1159/000504626. View

18.

Bloomfield M, Ashok A, Volkow N, Howes O . The effects of Δ-tetrahydrocannabinol on the dopamine system. Nature. 2016; 539(7629):369-377. PMC: 5123717. DOI: 10.1038/nature20153. View

19.

McGinty J, Bache A, Coleman N, Sun W . The Role of BDNF/TrkB Signaling in Acute Amphetamine-Induced Locomotor Activity and Opioid Peptide Gene Expression in the Rat Dorsal Striatum. Front Syst Neurosci. 2011; 5:60. PMC: 3143721. DOI: 10.3389/fnsys.2011.00060. View

20.

Jockers-Scherubl M, Danker-Hopfe H, Mahlberg R, Selig F, Rentzsch J, Schurer F . Brain-derived neurotrophic factor serum concentrations are increased in drug-naive schizophrenic patients with chronic cannabis abuse and multiple substance abuse. Neurosci Lett. 2004; 371(1):79-83. DOI: 10.1016/j.neulet.2004.08.045. View